Kerri M. Winters-Stone, PhD, on Peripheral Neuropathy: High Prevalence Among Female Survivors
2016 Cancer Survivorship Symposium
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).
Dana Barnea, MD
Dana Barnea, MD, of Memorial Sloan Kettering Cancer Center, discusses data that suggest annual palpation of the thyroid is an adequate and safe means of screening childhood and young adult cancer survivors, a population at high risk for this type of cancer (Abstract 254).
Christopher J. Recklitis, PhD, MPH
Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute, discusses these side effects and some practical approaches to managing them with educational, medical, behavioral, and lifestyle interventions.
Tim A. Ahles, PhD
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Lewis E. Foxhall, MD
Lewis E. Foxhall, MD, of The University of Texas MD Anderson Cancer Center, summarizes this session in which presenters covered a range of issues, including the medical home, tools to facilitate communication with cancer survivors, EMRs, reimbursement, and coordinating care with primary care providers (Abstract 76 was presented in this session).
Patricia A. Ganz, MD
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses the limited sensitivity and specificity of surveillance testing for cancer recurrence and finding a better way to reassure patients about their continuing care.
